VBL sees survival benefit in GBM Phase I/II

VBL Therapeutics Ltd. (NASDAQ:VBLT) said preliminary data from a Phase I/II study of its VB-111 to treat recurrent glioblastoma multiforme (rGBM) suggest the gene-based dual anti-angiogenic and vascular disruptive agent (VDA) improved overall survival.

Patients initially received VB-111, then got a combination of VB-111 and Avastin bevacizumab from Roche (SIX:ROG; OTCQX:RHHBY) or Avastin alone after the disease progressed. Median overall survival was 504 days for the combo group compared to 235 days in patients who switched from VB-111 to Avastin alone. The data were from 46 patients, half of whom were given the combo and half only Avastin after disease progression. ...